King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
Ocul Immunol Inflamm. 2010 Jun;18(3):226-32. doi: 10.3109/09273948.2010.483314.
To describe the clinical outcome of refractory ocular Behçet disease with adalimumab therapy.
Retrospective review of records.
Twenty-one eyes of 11 male patients with ocular Behçet disease received adalimumab therapy. Of the 21 eyes, 17 had improvement of visual acuity by more than 3 lines after the average follow-up of 10.8 months. Ten out of 11 patients showed complete resolution of inflammation by 4 weeks. The dosages of corticosteroids and immunosuppressive drugs were reduced in most of the patients and stopped altogether in 3 and 6 patients, respectively. One patient on infliximab showed improvement of inflammation after switching over to adalimumab. No serious side effects were observed in any of the patients.
Adalimumab appears to be effective in Behçet disease. It has been shown to improve visual acuity and also to have a corticosteroid and immunosuppressive sparing effect. It can induce and maintain sustained remission of the disease.
描述阿达木单抗治疗难治性眼型贝赫切特病的临床疗效。
回顾性病历分析。
11 名男性眼型贝赫切特病患者的 21 只眼接受了阿达木单抗治疗。平均随访 10.8 个月后，17 只眼的视力提高超过 3 行。11 名患者中有 10 名在 4 周内完全缓解炎症。大多数患者的皮质类固醇和免疫抑制剂剂量减少，3 名和 6 名患者分别停用这两种药物。1 名使用英夫利昔单抗的患者在改用阿达木单抗后炎症得到改善。所有患者均未出现严重不良反应。
阿达木单抗治疗贝赫切特病有效，可改善视力，且具有皮质类固醇和免疫抑制剂的节省作用，可诱导并维持疾病的持续缓解。
Zotero 插件